| Released | Contributor | Author | Title | Pages | Price |
| 7-Dec-2009 | Market Edge |
N/A
| Market Edge Equity Research Report | 4 |
$10 |
| 6-Dec-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 6-Dec-2009 | PriceTarget Research, Inc. |
N/A
| Shire has a current Overall Rating of B (Positive). | 7 |
$25 |
| 5-Dec-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 5-Dec-2009 | Standard & Poor's STARS Report |
N/A
| Shire Plc ADS | 8 |
$35 |
| 4-Dec-2009 | Pechala's Reports | Lubomir Pechala | SHIRE PHARMACEUTICALS GROUP PLC SPO (SHPGY=US) 2-weeks forecast | 1 |
$10 |
| 4-Dec-2009 | Pechala's Reports | Frantisek Pechala | SHIRE PHARMACEUTICALS GROUP PLC SPO (SHPGY=US) 12-months forecast | 1 |
$15 |
| 3-Dec-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: AGN , FRX , NVO , SHPGY , WPI -- DRUGS | 3 |
$4 |
| 3-Dec-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: SHIRE PLC -- SHPGY | 1 |
$4 |
| 3-Dec-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Plunkett's Health Care Technologies Overview 2010 (Summary) | 80 |
$199 |
0.22% Nasdaq 0.00%
Research Reports
